Allogene Therapeutics Stock Analysis

Allogene Stock Analysis Notes

About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.25. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 2.09. The entity had not issued any dividends in recent years. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 344 people. For more info on Allogene Therapeutics please contact David Chang at 650 457 2700 or go to https://www.allogene.com.

Allogene Therapeutics Investment Alerts

Allogene Therapeutics Upcoming and Recent Events

Allogene Largest EPS Surprises

View All Earnings Estimates

Allogene Stock Institutional Investors

Note, although Allogene Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Allogene Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 591.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allogene Therapeutics's market, we take the total number of its shares issued and multiply it by Allogene Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Allogene Profitablity

Management Efficiency

Allogene Therapeutics has return on total asset (ROA) of (0.2684) % which means that it has lost $0.2684 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5551) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics' management efficiency ratios could be used to measure how well Allogene Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.55. At this time, Allogene Therapeutics' Total Assets are very stable compared to the past year. As of the 18th of April 2024, Non Current Assets Total is likely to grow to about 245.6 M, while Net Tangible Assets are likely to drop about 732.1 M.

Technical Drivers

As of the 18th of April 2024, Allogene Therapeutics shows the Risk Adjusted Performance of 0.0407, mean deviation of 3.3, and Downside Deviation of 4.01. Allogene Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Allogene Therapeutics, which can be compared to its peers. Please confirm Allogene Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Allogene Therapeutics is priced correctly, providing market reflects its regular price of 3.46 per share. Given that Allogene Therapeutics has jensen alpha of 0.084, we suggest you to validate Allogene Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Allogene Therapeutics Price Movement Analysis

Allogene Therapeutics Insider Trading Activities

Allogene Therapeutics Predictive Daily Indicators

Allogene Therapeutics Corporate Filings

Allogene Therapeutics Forecast Models

Allogene Therapeutics' time-series forecasting models are one of many Allogene Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allogene Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Allogene Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Allogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Allogene Therapeutics. By using and applying Allogene Stock analysis, traders can create a robust methodology for identifying Allogene entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Allogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Allogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Allogene Therapeutics stock analysis indicators help investors evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By understating and applying Allogene Therapeutics stock analysis, traders can identify Allogene Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.